Log in

NASDAQ:EPZMEpizyme News Headlines

$14.79
-0.18 (-1.20 %)
(As of 07/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.48
Now: $14.79
$15.15
50-Day Range
$14.97
MA: $17.22
$20.46
52-Week Range
$9.73
Now: $14.79
$27.82
Volume1.24 million shs
Average Volume1.12 million shs
Market Capitalization$1.49 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Headlines

Epizyme (NASDAQ EPZM) News Headlines

Source:
DateHeadline
Epizyme Inc (NASDAQ:EPZM) Expected to Announce Earnings of -$0.56 Per ShareEpizyme Inc (NASDAQ:EPZM) Expected to Announce Earnings of -$0.56 Per Share
www.americanbankingnews.com - July 14 at 4:33 PM
Epizyme Inc (NASDAQ:EPZM) Receives Average Rating of "Hold" from AnalystsEpizyme Inc (NASDAQ:EPZM) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 9 at 2:20 AM
Epizyme (NASDAQ:EPZM) Lowered to "Strong Sell" at BidaskClubEpizyme (NASDAQ:EPZM) Lowered to "Strong Sell" at BidaskClub
www.marketbeat.com - July 7 at 1:27 AM
Epizyme A Buy For Tazverik And Epigenetic Platform - Seeking AlphaEpizyme A Buy For Tazverik And Epigenetic Platform - Seeking Alpha
seekingalpha.com - July 1 at 9:37 AM
Epizyme Inc (NASDAQ:EPZM) CEO Sells $77,083.95 in StockEpizyme Inc (NASDAQ:EPZM) CEO Sells $77,083.95 in Stock
www.americanbankingnews.com - June 30 at 11:32 AM
Paolo Tombesi Sells 1,805 Shares of Epizyme Inc (NASDAQ:EPZM) StockPaolo Tombesi Sells 1,805 Shares of Epizyme Inc (NASDAQ:EPZM) Stock
www.marketbeat.com - June 30 at 11:32 AM
Monday 6/29 Insider Buying Report: BSIG, EPZMMonday 6/29 Insider Buying Report: BSIG, EPZM
www.nasdaq.com - June 30 at 8:23 AM
Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares - Yahoo FinanceInsider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares - Yahoo Finance
finance.yahoo.com - June 28 at 1:00 PM
Insider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More SharesInsider Buying: The Epizyme, Inc. (NASDAQ:EPZM) Independent Chairman Just Bought 49% More Shares
finance.yahoo.com - June 28 at 1:00 PM
Epizyme Inc (NASDAQ:EPZM) Director David M. Mott Buys 62,019 SharesEpizyme Inc (NASDAQ:EPZM) Director David M. Mott Buys 62,019 Shares
www.americanbankingnews.com - June 26 at 8:31 PM
$4.45 Million in Sales Expected for Epizyme Inc (NASDAQ:EPZM) This Quarter$4.45 Million in Sales Expected for Epizyme Inc (NASDAQ:EPZM) This Quarter
www.americanbankingnews.com - June 24 at 3:43 AM
Insider Selling: Epizyme Inc (NASDAQ:EPZM) CEO Sells 20,000 Shares of StockInsider Selling: Epizyme Inc (NASDAQ:EPZM) CEO Sells 20,000 Shares of Stock
www.americanbankingnews.com - June 22 at 9:03 PM
Epizyme Inc (NASDAQ:EPZM) Insider Matthew Ros Sells 112,003 SharesEpizyme Inc (NASDAQ:EPZM) Insider Matthew Ros Sells 112,003 Shares
www.americanbankingnews.com - June 22 at 8:31 PM
Epizyme (NASDAQ:EPZM) Shares Gap Down  Following Analyst DowngradeEpizyme (NASDAQ:EPZM) Shares Gap Down Following Analyst Downgrade
www.marketbeat.com - June 22 at 1:53 PM
 Brokerages Anticipate Epizyme Inc (NASDAQ:EPZM) to Post -$0.56 Earnings Per Share Brokerages Anticipate Epizyme Inc (NASDAQ:EPZM) to Post -$0.56 Earnings Per Share
www.americanbankingnews.com - June 22 at 9:50 AM
Epizymes shares fall after receiving new FDA approval for cancer drugEpizyme's shares fall after receiving new FDA approval for cancer drug
www.msn.com - June 21 at 7:22 AM
BRIEF-Roche Gets FDA Approval For Cobas EZH2 Mutation Test As Companion Diagnostic For Tazverik Developed By Epizyme - ReutersBRIEF-Roche Gets FDA Approval For Cobas EZH2 Mutation Test As Companion Diagnostic For Tazverik Developed By Epizyme - Reuters
www.reuters.com - June 19 at 7:07 PM
FDA OK companion diagnostic for Epizymes Tazverik - Seeking AlphaFDA OK companion diagnostic for Epizyme's Tazverik - Seeking Alpha
seekingalpha.com - June 19 at 2:06 PM
Epizymes shares fall after receiving new FDA approval for cancer drug - MarketWatchEpizyme's shares fall after receiving new FDA approval for cancer drug - MarketWatch
www.marketwatch.com - June 19 at 2:06 PM
Epizyme's shares fall after receiving new FDA approval for cancer drugEpizyme's shares fall after receiving new FDA approval for cancer drug
finance.yahoo.com - June 19 at 9:00 AM
Cignas Tie-Up to Offer Improved Healthcare in North Alabama - NasdaqCigna's Tie-Up to Offer Improved Healthcare in North Alabama - Nasdaq
www.nasdaq.com - June 19 at 12:24 AM
Cowen Defends Epizyme (EPZM) on Label Concerns - StreetInsider.comCowen Defends Epizyme (EPZM) on Label Concerns - StreetInsider.com
www.streetinsider.com - June 18 at 7:23 PM
FDA OKs Epizymes tazemetostat for treatment-resistant follicular lymphoma - Seeking AlphaFDA OKs Epizyme's tazemetostat for treatment-resistant follicular lymphoma - Seeking Alpha
seekingalpha.com - June 18 at 2:23 PM
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma - Business WireEpizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma - Business Wire
www.businesswire.com - June 18 at 2:23 PM
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular LymphomaEpizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma
finance.yahoo.com - June 18 at 2:23 PM
The Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahns Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions - BenzingaThe Daily Biotech Pulse: Eloxx Resumes Cystic Fibrosis Study, Rexahn's Reverse Merger, Ultragenyx, Epizyme Await FDA Decisions - Benzinga
www.benzinga.com - June 18 at 9:23 AM
Hedge Funds Aren’t Done Buying Epizyme Inc (EPZM) - Yahoo FinanceHedge Funds Aren’t Done Buying Epizyme Inc (EPZM) - Yahoo Finance
finance.yahoo.com - June 17 at 6:50 PM
2 Top Cancer Treatment Stocks to Buy in June - Motley Fool2 Top Cancer Treatment Stocks to Buy in June - Motley Fool
www.fool.com - June 16 at 9:14 AM
Call Buying Activity in Epizyme (EPZM) Targets 57% Upside in Shares Through Mid-August -Susquehanna - StreetInsider.comCall Buying Activity in Epizyme (EPZM) Targets 57% Upside in Shares Through Mid-August -Susquehanna - StreetInsider.com
www.streetinsider.com - June 13 at 12:07 AM
Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound? - Yahoo FinanceEpizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
finance.yahoo.com - June 3 at 7:33 PM
Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound?Epizyme (EPZM) Down 4.4% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - June 3 at 2:32 PM
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates - Yahoo FinanceAttention Biotech Investors: Mark Your Calendar For June PDUFA Dates - Yahoo Finance
finance.yahoo.com - June 1 at 7:34 PM
Epizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced - Seeking AlphaEpizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced - Seeking Alpha
seekingalpha.com - May 27 at 12:48 PM
Epizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions - Yahoo FinanceEpizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions - Yahoo Finance
finance.yahoo.com - May 14 at 12:52 PM
Epizyme (EPZM): Strong Industry, Solid Earnings Estimate RevisionsEpizyme (EPZM): Strong Industry, Solid Earnings Estimate Revisions
finance.yahoo.com - May 14 at 12:52 PM
BRIEF-Epizyme To Present Data From Tazemetostat Clinical Program During 2020 ASCO Virtual Scientific Program - ReutersBRIEF-Epizyme To Present Data From Tazemetostat Clinical Program During 2020 ASCO Virtual Scientific Program - Reuters
www.reuters.com - May 13 at 9:16 PM
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program - Business WireEpizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program - Business Wire
www.businesswire.com - May 13 at 9:16 PM
Epizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific ProgramEpizyme to Present Data from Tazemetostat Clinical Program during the 2020 ASCO Virtual Scientific Program
finance.yahoo.com - May 13 at 9:16 PM
Allogenes (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses - Yahoo FinanceAllogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses - Yahoo Finance
finance.yahoo.com - May 7 at 12:26 PM
Allogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline ProgressesAllogene's (ALLO) Q1 Loss Widens Y/Y, Pipeline Progresses
finance.yahoo.com - May 7 at 12:26 PM
Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT - Yahoo FinanceEdited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT - Yahoo Finance
finance.yahoo.com - May 5 at 5:28 PM
Epizymes (EPZM) Q1 Earnings Beat Estimates, Revenues Miss - Yahoo FinanceEpizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss - Yahoo Finance
finance.yahoo.com - May 5 at 5:28 PM
Epizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues MissEpizyme's (EPZM) Q1 Earnings Beat Estimates, Revenues Miss
finance.yahoo.com - May 5 at 5:28 PM
Edited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMTEdited Transcript of EPZM earnings conference call or presentation 4-May-20 1:00pm GMT
finance.yahoo.com - May 5 at 8:49 AM
Epizyme Inc (EPZM) Q1 2020 Earnings Call Transcript - Motley FoolEpizyme Inc (EPZM) Q1 2020 Earnings Call Transcript - Motley Fool
www.fool.com - May 4 at 10:44 PM
Epizyme Inc (EPZM) Q1 2020 Earnings Call TranscriptEpizyme Inc (EPZM) Q1 2020 Earnings Call Transcript
finance.yahoo.com - May 4 at 10:44 PM
Epizyme Reports Business Progress and First Quarter 2020 Financial Results - Business WireEpizyme Reports Business Progress and First Quarter 2020 Financial Results - Business Wire
www.businesswire.com - May 4 at 5:44 PM
Epizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo FinanceEpizyme (EPZM) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
finance.yahoo.com - May 4 at 5:44 PM
BRIEF-Epizyme Posts Q1 Loss Per Share Of $0.51 - ReutersBRIEF-Epizyme Posts Q1 Loss Per Share Of $0.51 - Reuters
www.reuters.com - May 4 at 12:43 PM
Epizyme (EPZM) Tops Q1 EPS by 23c, Revenues Miss - StreetInsider.comEpizyme (EPZM) Tops Q1 EPS by 23c, Revenues Miss - StreetInsider.com
www.streetinsider.com - May 4 at 12:43 PM
This page was last updated on 7/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.